EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

Jaekyung Cheon, Baek-Yeol Ryoo, Hong Jae Chon, Hyung-Don Kim, Min-Hee Ryu, Kyu-Pyo Kim, Beodeul Kang, Richard S Finn, Stephen Lam Chan, Changhoon Yoo

Liver Cancer · 21.01.2025 · 14 (4) · 446-455

DOI: 10.1159/000543666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 21.01.2025. Verfasst von Jaekyung Cheon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atezolizumab-bevacizumab (Atezo-Bev) has become the standard first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, data on subsequent treatment after Atezo-Bev failure are lacking. We aimed to investigate the efficacy and safety of regorafenib for uHCC progression after first-line Atezo-Bev.

Methods

This investigator-initiated, single-arm, phase 2 trial involved two academic centers in Korea. Eligibility criteria included a diagnosis of HCC, prior treatment with at least 2 cycles of Atezo-Bev, and Child-Pugh A liver function. Eligible patients received regorafenib 160 mg once daily for 3 weeks of every 4-week cycle (i.e., 3 weeks on, 1 week off) until progressive disease or intolerable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate, disease control rate according to RECIST v1.1, overall survival (OS), and treatment-related adverse events.

Results

Forty patients were enrolled from December 2021 through May 2023. The median follow-up duration was 10.1 months (95% confidence interval [CI]: 8.3–12.0). The median PFS was 3.5 months (95% CI: 3.0–3.9). The median OS was 10.5 months (95% CI: 7.1–13.8), and the 6-month OS rate was 65.0%. The objective response rate and disease control rate were 10.0% and 82.5%, respectively. The most common grade 3–4 treatment-related adverse event was thrombocytopenia (5.0%). When stratified according to time to progression on prior Atezo-Bev (first quartile [

Schlagwörter

Stichwörter der Autor:innen

AtezolizumabBevacizumabHepatocellular carcinomaRegorafenibTyrosine kinase inhibitor

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.
  • Department of Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.
  • Department of Clinical Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.

Zitieren

APA

Cheon, J., Ryoo, B. Y., Chon, H. J., Kim, H. D., Ryu, M. H., Kim, K. P., Kang, B., Finn, R. S., Chan, S. L., & Yoo, C. (2025). Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab. Liver Cancer, 14(4), 446-455. https://doi.org/10.1159/000543666

Vancouver

Cheon J, Ryoo BY, Chon HJ, Kim HD, Ryu MH, Kim KP, et al. Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab. Liver Cancer. 2025;14(4):446-455. doi:10.1159/000543666

BibTeX
@article{Cheon2025,
  author = {Cheon, Jaekyung and Ryoo, Baek-Yeol and Chon, Hong Jae and Kim, Hyung-Don and Ryu, Min-Hee and Kim, Kyu-Pyo and Kang, Beodeul and Finn, Richard S and Chan, Stephen Lam and Yoo, Changhoon},
  title = {Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab},
  journal = {Liver Cancer},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {446--455},
  doi = {10.1159/000543666}
}
Kostenlos starten →